Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.02 -0.61 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.63 | 52 Week High | $45.58 | |||
| Open | $50.19 | 52 Week Low | $37.82 | |||
| Day High | $50.45 | P/E | N/A | |||
| Day Low | $49.91 | EPS | $0.00 | |||
| Volume | 3,340,597 | |||||
